Catalyst Pharmaceuticals, Inc. (CPRX) |
14.68 -0.44 (-2.91%) 04-25 16:00 |
Open: | 14.82 |
High: | 15.01 |
Low: | 14.585 |
Volume: | 868,239 |
Market Cap: | 1,730(M) |
PE Ratio: | 23.3 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 17.43 |
Resistance 1: | 16.34 |
Pivot price: | 15.36 |
Support 1: | 14.59 |
Support 2: | 12.13 |
52w High: | 17.77 |
52w Low: | 11.09 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
EPS | 0.630 |
Book Value | 3.620 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 17.93 |
Operating Margin (%) | 37.71 |
Return on Assets (ttm) | 12.8 |
Return on Equity (ttm) | 20.8 |
Wed, 24 Apr 2024
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Tue, 23 Apr 2024
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Mon, 22 Apr 2024
Results: Catalyst Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Movies Canada
Mon, 22 Apr 2024
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 - Yahoo Canada Finance
Sat, 20 Apr 2024
Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong ... - Yahoo Movies Canada
Fri, 19 Apr 2024
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |